GlassScriptPhysician profile
Paul Elliott
NPI 1629874474
$1,334.43
in general payments reported to CMS, 2019-2025
13 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.56 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $349.91 | 2025 | Fanapt |
| Alkermes, INC. | $252.88 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $135.52 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $104.68 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.28 | 2025 | Caplyta |
| Lundbeck LLC | $88.80 | 2025 | Abilify Maintena, Rexulti |
| Abbvie INC. | $86.09 | 2025 | |
| Noven Therapeutics, LLC | $57.43 | 2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $55.13 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $37.91 | 2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $30.72 | 2025 | Qelbree |
| Neuronetics, INC. | $25.37 | 2025 | Neurostar Tms Therapy System |
| Indivior INC. | $19.71 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.